[{"Assets_0_Q2_USD":253964000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":20970000.0,"NetIncomeLoss_1_Q2_USD":7094000.0,"NetIncomeLoss_2_Q2_USD":15200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":42496000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":42472000.0,"StockholdersEquity_0_Q2_USD":181645000.0,"EarningsPerShareBasic_1_Q2_USD":0.17,"EarningsPerShareBasic_2_Q2_USD":0.36,"Ticker":"VIVO","CIK":"794172","name":"MERIDIAN BIOSCIENCE INC","OfficialName":"Meridian Bioscience Inc. Common Stock","form":"10-Q","period":"20190331","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1192599275.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190507"}]